AVITA Medical Q4 revenue $18.4M (+30% YoY), net loss $11.6M; FY2025 guidance $100-106M

AVITA Medical, Inc.

2024-FY EPS reported -$2.39 revenue$64,251,000

Q4 commercial revenue $18.4M (+30% YoY); gross margin 87.6%.
Net loss $11.6M ($0.44 loss per share) vs $7.1M loss in Q4 2023.
FY2025 revenue guidance $100-106M (55-65% growth); expects GAAP profitability in Q4 2025.
Amended OrbiMed credit agreement; adjusted revenue covenants for 2025-2026; issued warrants for 145,180 shares at $0.01/share.
FDA clearances: Cohealyx (Dec 2024) and RECELL GO mini (Dec 2024); full Cohealyx launch by April 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.